Evidence map›Paper›PMID 34275115›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2021

Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States.

Kristina S Boye, Elif Tokar Erdemir, Nathan Zimmerman, Abraham Reddy, Brian D Benneyworth, Matan C Dabora, Emily R Hankosky, M Angelyn Bethel, Callahan Clark, Cody J Lensing and 4 more

Open access · goldAbstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. The Impact of Comorbid Dementia and Diabetes Mellitus on Hospital Patients' Outcomes: A Systematic Review and Meta-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Kristina S BoyeEli Lilly and Company, Indianapolis, IN, USA.
Elif Tokar ErdemirOptumLabs at UnitedHealth Group, Minneapolis, MN, USA. eliftokar@gmail.com.
Nathan ZimmermanOptumLabs at UnitedHealth Group, Minneapolis, MN, USA.
Abraham ReddyOptumLabs at UnitedHealth Group, Minneapolis, MN, USA.
Brian D BenneyworthEli Lilly and Company, Indianapolis, IN, USA.
Matan C DaboraEli Lilly and Company, Indianapolis, IN, USA.
Emily R HankoskyEli Lilly and Company, Indianapolis, IN, USA.
M Angelyn BethelEli Lilly and Company, Indianapolis, IN, USA.
Callahan ClarkOptumLabs at UnitedHealth Group, Minneapolis, MN, USA.
Cody J LensingOptumLabs at UnitedHealth Group, Minneapolis, MN, USA.
Scott SailerOptumLabs at UnitedHealth Group, Minneapolis, MN, USA.
Ramira San JuanOptumLabs at UnitedHealth Group, Minneapolis, MN, USA.
Robert J HeineEli Lilly and Company, Indianapolis, IN, USA.
Lida EtemadOptumLabs at UnitedHealth Group, Minneapolis, MN, USA.
Eli Lilly (United States) · USOptum (United States) · USUnitedHealth Group (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiabetes has been identified as a high-risk comorbidity for COVID-19 hospitalization. We evaluated additional risk factors for COVID-19 hospitalization and in-hospital mortality in a nationwide US database.

methodsThis retrospective study utilized the UnitedHealth Group Clinical Discovery Database (January 1, 2019-July 15, 2020) containing de-identified nationwide administrative claims, SARS-CoV-2 laboratory test results, and COVID-19 inpatient admissions data. Logistic regression was used to understand risk factors for hospitalization and in-hospital mortality among people with type 2 diabetes (T2D) and in the overall population. Robustness of associations was further confirmed by subgroup and sensitivity analyses in the T2D population.

resultsA total of 36,364 people were identified who were either SARS-CoV-2

conclusionIn this nationwide US analysis, T2D was identified as an independent risk factor for COVID-19 complications. Many factors conferred similar risk of hospitalization across both populations; however, particular diabetes medications may be markers for differential risk. The insights on comorbidities and medications may inform population health initiatives, including prevention efforts for high-risk patient populations such as those with T2D.

Indexed as

Claim-based analysisCOVID-19Risk factorsSARS-CoV-2Type 2 diabetes

Identifiers

PMID34275115
PMCPMC8286432
OpenAlexW3185276155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.